On slide nine, let me highlight the positive results of Dupixent in patients with chronic spontaneous urticaria announced today. CSU bears the hallmarks of type two inflammation and is characterized by hives and/or skin swelling and is associated with intense itch. This chronic disease has a potentially severe impact on quality of life and is typically treated with antihistamines. However, for up to 50% of people living with CSU, their disease remains uncontrolled, and an estimated 300,000 moderate to severe patients are eligible for biologics in the U.S. Putting this into context, the eligible population is as large as the number of patients on Dupixent globally today.